1Redl, H, Dinges, HP, Schlag, G. Quantitative estimation of leukostasis in the posttraumatic lung-canine and human autopsy data. Prog Clin Biol Res 1987; 236A: 43–53.
2Schlag, G, Redl, H. Die Leukostse in der Lunge beim hypovolamisch-traumatischen Schock. Anaesthetist 1980; 29: 606–12.
3Grey, HM, Chesnut, R. Antigen processing and presentation to T cells. Immunol Today 1985; 3: 101–106.
4Ashwell, JD, Schwartz, RH. T-cell recognition of antigen and the Ia molecule as a ternary complex. Nature 1986; 320: 176–79.
5Baumhuter, S, Bron, C, Corradin, G. Different antigen-presenting cells differ in their capacity to induce lymphokine production and proliferation of an apocytochrome c-specific T-cell clone. J Immunol 1985; 135: 989–94.
6Miyajama, A, Miyatake, S, Schreurs, J, DeVries, J, Arai, N, Yokota, T et al. Coordinate regulation of immune and inflammatory responses by T-cell-derived lymphokines. FASEB 1988; 2: 2462–73.
7Meuer, SC, Acuto, O, Hercend, T, Schlossman, SF, Reinherz, EL. The human T-cell receptor. Ann Rev Immunol 1984; 2: 23–50.
8Copper, MD, Kearney, JF, Gathings, WE, Lawton, AR. Effects of anti-Ig antibodies and the development and differentiation of B cells. In: Moller, G ed, Immunological reviews. Copenhagen: Munkgaard, 1980: 29–53.
9Wall, R, Kuehl, M. Biosynthesis and regulation of immunoglobulins. Ann Rev Immunol 1983; 1: 393–422.
10Howard, M, Paul, WE. Regulation of B-cell growth and differentiation by soluble factors. Ann Rec Immunol 1983; 1: 307–33.
11Owen, M. Major histocompatibility complex. In: Roitt, I, Brostoff, J, Male, D eds. Immunology, 2nd ed. London: Churchill Livingstone, 1989: 4.1–4.12.
12Colletti, LM, Remick, DG, Burtch, GD, Kunkel, SL, Strieter, RM, Campbell, DA. Role of tumor necrosis factor alpha in the pathophysiologic alter hepatic ischemia reperfusion injury in the rat. J Clin Invest 1990; 85: 1936–43.
13Redl, H, Schlag, G, Bahrami, S, Schade, U, Ceska, M, Stutz, P. Plasma neutrophil-activating peptide-1/ interleukin-8 and neutrophil elastase in a primate bactermia model. J Inf Dis 1991; 164: 383–88.
14Schlag, G, Redl, H, Dinges, HP, Davies, J, Radmore, K. Bacterial translocation in a baboon model of hypovolemic-traumatic shock. In: Schlag, G, Redl, H, Siegel, JH, Traber, DL eds, Shock, sepsis and organ failure - second Wiggers Bernard conference. Berlin, Heidelberg: Springer-Verlag, 1991: 53–83.
15Scuderi, P, Lam, KS, Ryan, KJ. Raised levels of tumor necrosis factor in parasitic infections. Lancet 1986; ii: 1364–65.
16Hesse, DG, Tracey, KJ, Fong, Y, Manogue, KR, Palladino, MA Jr, Cerami, A et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988; 166: 147–53.
17Waage, A, Halstensen, A, Espevik, T. Association between tumour necrosis factor in serum and fetal outcome in patients with meningococcal disease. Lancet 1987; i: 355–57.
18Haeffner-Cavaillon, JM, Ciancioni, C, Bacle, F, Delons, S, Kazatchkine, MD. In vivo induction of interleukin-l during hemodialysis. Kidney Int 1989; 35: 1212–18.
19Haeffner-Cavaillon, N, Roussellier, N, Ponzio, O, Carreno, MP, Laude, M, Carpentier, A et al. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Th Card Surg 1989; 98: 1100–106.
20Beutler, B, Cerami, A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379–85.
21Debets, JMH, Kampmeijer, R, van der Linden, MPMH, Buurman, WA, van der Linden, CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17: 489–94.
22Waage, A, Brandtzaeg, P, Halstensen, A, Kierule, P, Espevik, T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1 and fatal outcome. J Exp Med 1989; 169: 333–38.
23Marano, MA, Fong, Y, Moldawer, LL, Wei, H, Calvano, SE, Tracey, KJ et al. Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet 1990; 170: 32–38.
24Cavaillon, JM, Fitting, C, Haeffner-Cavaillon, N. Recombinant C5a enchances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990; 20: 253–57.
25Scholz, W, McClurg, MR, Cardenas, GJ, Smith, M, Noonan, DJ, Hugli, THE et al. C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol 1990; 57: 297–307.
26Lemaire, I. Neurotensin enchances IL-1 production by activated alveolar macrophages. J Immunol 1988; 140: 2983–88.
27Traycey, KJ, Fong, Y, Hesse, DG, Manogue, KR, Lee, AT, Kuo, GC et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662–64.
28Emerson, THE, Lindsey, DC, Jesmok, GJ, Duerr, ML, Fournel, MA. Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxic baboon model. Circ Shock 1992; 38: 37–84.
29Kishimoto, T. The biology of interleukin-6. Blood 1989; 74: 1–10.
30Larsen, CG, Anderson, AO, Appella, E, Oppenheim, JJ, Matsushima, K. The neutrophil activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243: 1464–66.
31Turner, M. Molecules which recognize antigen. In: Roitt, I, Brostoff, J, Male, D eds. Immunology, 2nd ed. London: Churchill Livingstone, 1989: 5.1–5.12.
32Ross, SC, Rosenthal, PJ, Berberich, HM, Densen, P. Killing of Neisseria meningtidis by human neutrophils: implications for normal and complement-deficient individuals. J Infect Dis 1987; 155: 1266–75.
33Ghebrehiwet, B, Müller-Eberhard, HJ. C3e: an acidic fragment of human C3 with leukocytosis inducing activity. J Immunol 1979; 123: 616–21.
34Mayer, MM. The complement system. Scientific Am 1973; 229: 54–66.
35Densen, P, Weiler, JM, Griffiss, JM, Hoffmann, LG. Familial properdin deficiency and fatal meningococcemia. N Engl J Med 1987; 316: 922–26.
36Molad, Y, Zimran, A, Sidi, Y, Pinkhas, J. Post-traumatic meningococcemia in a patient with deficiency of the C7 complement component. Isr J Med Sci 1990; 26: 90–92.
37Alper, CA, Rosen, FG. Inherited deficiencies of complement proteins in man. Springer Semin Immunopathol 1984; 7: 251–61.
38Hugli, TE. Complement anaphylatoxins as plasma mediators, spasmongens and chemotaxins. In: Bing, DH ed, The chemistry and physiology of human plasma proteins. New York: Pergamon Press, 1979: 255–80.
39Grant, JA, Dupree, E, Goldman, AS, Schultz, DR, Jackson, AL. Complement-mediated release of histamine from human leukocytes. J Immunol 1975; 114: 1101–106.
40Hugli, TE, Marceau, F. Effects of the C5a anaphylatoxin and its relationship to cyclo-oxygenase metabolites in rabbit vascular strips. Br J Pharmacol 1985; 84: 725–33.
41Hachfeld del Balzo, U, Levi, R, Polley, MJ. Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc Natl Acad Sci USA 1985; 82: 886–90.
42Webster, RO, Hong, SR, Johnston, Jr RB, Henson, PM. Biological effects of the human complement fragments C5a and C5a desArg on neutrophil function. Immunopharmac 1980; 2: 201–19.
43Fearon, DT, Collins, LA. Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. J Immunol 1983; 130: 370–75.
44Lee, J, Hakim, RM, Fearon, DT. Increased expression of the C3b receptor and complement activation during hemodialysis. Clin Exp Immunol 1984; 56: 205–14.
45Goldstein, IM, Brai, M, Osler, AG, Weissmann, G. Lysosomal enzyme release from human leukocytes: mediation by the alternate pathway of complement activation. J Immunol 1973; 111: 33–37.
46Goodman, MG, Chenoweth, DE, Weigle, WO. Induction of interleukin 1 secretion and enchancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors. J Exp Med 1982; 1156: 912–17.
47Henson, PM, Larsen, GL, Webster, RO, Mitchell, BC, Goins, AJ, Henson, JE. Pulmonary microvascular alterations and injury induced by complement fragments: synergistic effect of complement activation, neutrophil sequestration, and prostaglandins. Ann N Y Acad Sci USA 1982; 384: 287–300.
48Fein, AM, Lippman, M, Hotzman, H, Eliraz, A, Goldberg, SK. The risk factors, incidence, and prognosis of ARDS following septicemia. Chest 1983; 83: 40–42.
49Parker, MM, Parillo, JE. Septic shock. Hemodynamics and pathogenesis. JAMA 1983; 250: 3324–27.
50Lachmann, PJ. Complement and disease. Rec Prog Med 1988; 79: 293–99.
51Dalmasso, AP. Complement in the pathophysiology and diagnosis of human disease. CRC Crit Rev Clin Lab Sci 1986; 24: 123–83.
52Redl, H, Schlag, G. Biochemical analysis in posttraumatic and postoperative organ failure. Prog Clin Biol Res 1989; 308: 649–72.
53Ognibene, FP, Martin, SE, Parker, MM, Schlesinger, T, Roach, P, Burch, C et al. Adult respiratory distress syndrome in patients with severe neutropenia. N Engl J Med 1986; 315: 547–51.
54Maunder, RJ, Hackman, RC, Riff, E, Albert, RK, Springmeyer, SC. Occurrence of the adult respiratory distress syndrome in neutropenic patients. Am Rev Respir Dis 1986; 133: 313–16.
55Laufe, MD, Simon, RH, Flint, A, Keller, JB. Adult respiratory distress syndrome in neutropenic patients. Am J Med 1986; 80: 1022–26.
56Müller-Eberhard, H. The membrane attack complex of complement. Ann Rev Immunol 1986; 4: 503–28.
57Hänsch, GM, Seitz, M, Betz, M. Effects of late acting complement components C5b-9 on human monocytes: release of prostanoids, oxygen radicals and a factor which induced cell proliferation. Int Arch Allergy Appl Immunol 1987; 82: 317–20.
58Hänsch, GM, Seitz, M, Martinotti, G, Betz, M, Rauterberg, EW, Gemsa, D. Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components. J Immunol 1984; 133: 2145–50.
59Langlois, PF, Gawryl, MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Artherosclerosis 1988; 70: 95–105.
60Langlois, PF, Sharon, GE, Gawryl, MS. Plasma concentrations of complement-activation complexes correlated with disease activity in patients diagnosed with isolated central nervous system vasculitis. J Allergy Clin Immunol 1989; 83: 11–16.
61Haeger, M, Bengtsson, A, Karlsson, K, Heideman, M. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid. Obstet Gynecol 1989; 73: 551–56.
62Kapp, A, Meske-Brand, S, Maly, FE, Müller, W. Komplement-aktiverung bei Patienten mit chronischer Polyartritis gemessenanhand des Komplement Bruckstuckes C3a im Plasma. Z Rheumatol 1984; 43: 103–105.
63Zilow, G, Sturm, JA, Rother, U, Kirschfink, M. Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. Clin Exp Immunol 1990; 79: 151–57.
64Roxvall, L, Bengtsson, A, Heideman, M. Anaphylatoxin generation in acute pancreatitis. J Surg Res 1989; 47: 138–43.
65Chenoweth, DE, Cooper, SW, Hugli, THE, Stewart, RW, Blackstone, EH, Kirklin, JW. Complement activation during cardiopulmonary bypass. Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981; 304: 497–503.
66Colomb, MG, Arlaud, GJ, Villiers, CL. Structure and activation of CI: current concepts. Complement 1984; 1: 69–80.
67Cooper, NR, Morrison, DC. Binding and activation of the first component of human complement by the lipid A region of lipopolysaccharides. J Immunol 1978; 120: 1862–68.
68Porter, RR, Reid, KBM. Activation of the complement system by antibody-antigen complexes: the classical pathway. Adv Protein Chem 1979; 33: 1–64.
69Tenner, AJ, Ziccardi, RJ, Cooper, NR. Antibody-independent Cl activation by E coli. J Immunol 1984; 133: 886–91.
70Ziccardi, RJ. The role of immune complexes in the activation of the first component of human complement. J Immunol 1984; 132: 283–88.
71Pangburn, MK. Activation of complement via the alternative pathway. Fed Proc 1983; 42: 139–43.
72Gelfand, JA, Donelan, M, Burke, JF. Preferential activation and depletion of the alternative complement pathway by burn injury. Ann Surg 1983; 198: 58–62.
73Joiner, KA. Role of complement in infectious disease. In: Ross, GD ed, Immunbiology of the complement system. New York: Academic Press, 1986; 183–95.
74Pangburn, MK, Schreiber, RD, Müller-Eberhard, HJ. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface. J Immunol 1983; 131: 1930–35.
75Hack, CE, Nuijens, JH, Felt-Bersma, RJF, Schreuder, WO, Eerenberg-Belmer, AJM, Paardekooper, J et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989; 86: 20–26.
76Weinburg, PF, Matthay, MA, Webster, RO, Roskos, KV, Goldstein, IM, Murray, JF. Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am Rev Respir Dis 1984; 130: 791–96.
77Slotman, GJ, Burchard, KW, Williams, JJ, D’Arrezzo, A, Yellin, SA. Interaction of prostaglandins, activated complement and granulocytes in clinical sepsis and hypotension. Surgery 1986; 99: 744–50.
78Langlois, PF, Gawryl, MS. Accentuated formation of the terminal C5b-9 complement complex in patient plasma precedes development of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138: 368–75.
79Glassman, AB, Bennett, CE, Christopher, JB, Self, S. Immunity during pregnancy: lymphocyte subpopulations and mitogen responsiveness. Ann Clin Lab Sci 1985; 15: 357–62.
80Coulam, CB, Silverfield, JC, Kazmar, RE, Fathman, CG. T lymphocyte subsets during pregnancy and the menstrual cycle. Am J Reprod Immunol 1983; 4: 88–90.
81Bach, JF. Transplantation immunity and cytotoxicity phenomena. In: Bach, JF, Schwartz, RS eds, Immunology, 2nd ed. New York: John Wiley and Sons, 1982: 399.
82Taylor, PV, Gowland, G, Hancock, KW, Scott, JS. Effect of length of gestation on maternal cellular immunity to human trophoblast antigens. Am J Obstet Gynecol 1976; 125: 528–31.
83Youtananukorn, V, Matangkasombut, P. Specific plasma factors blocking human maternal cell-mediated immune reaction to placental antigens. Nature New Biol 1973; 242: 110–11.
84Toder, V, Nebel, L, Gleicher, N. Studies of natural killer cells in pregnancy. I. Analysis at the single cell level. J Clin Lab Immunol 1984; 14: 123–27.
85Gregory, CD, Shah, LP, Lee, H, Scott, IV, Golding, PR. Gytotoxic reactivity of human natural killer (NK) cells during normal pregnancy: a longitudinal study. J Clin Lab Immunol 1985; 18: 175–81.
86Pitkin, RM, Witte, DL. Platelet and leukocyte counts in pregnancy. JAMA 1979; 242: 2696–98.
87Plum, J, Thierry, M, Sabre, L. Distribution of mononuclear cells during pregnancy. Clin Exp Immunol 1978; 31: 45–49.
88Krause, PJ, Ingardia, CJ, Pontius, LT, Malech, HL, LoBello, TM, Maderazo, EG. Host defence during pregnancy: neutrophil chemotaxis and adherence. Am J Obstet Gynecol 1987; 157: 274–80.
89Greer, IA, Haddad, NG, Dawes, J, Johnstone, FD, Calder, AA. Neutrophil activation in pregnancy-induced hypertension. Br J Obstet Gynaecol 1989; 96: 978–82.
90Haeger, M, Unander, M, Norder-Hansson, B, Tylman, M, Bengtsson, A. Complement, neutrophil and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 1992; 79: 19–26.
91Schröksnadel, H, Herold, M, Steckel-Berger, G, Fuchs, D, Wachter, H, Dapunt, O. Zellvermittelte Immunitätbei schwangerschaftsinduzierten Hochdruckerkrankungen (Cell-mediated immunity in hypertensive disorders of pregnancy). Geburtsh u Frauenheilk 1992; 52: 592–95.
92Hunt, JS, Fishback, JL. Amniochorion: immunological aspects - a review. Am J Reprod Immunol 1989; 21: 114–18.
93Ellis, S. HLA-G: at the interface. Am J Reprod Immunol 1990; 23: 84–86.
94Opsjön, S-L, Wathen, NC, Tingulstad, S, Wiedswang, G, Sundan, A, Waage, A et al. Tumor necrosis factor, interleukin-1, and interleukin-6 in normal human pregnancy. Am J Obstet Gynecol 1993; 169: 397–404.
95Marolis, GB, Buckley, RH, Younger, JB. Serum immunoglobulin concentrations during normal pregnancy. Am J Obstet Gynecol 1971; 109: 971–76.
96Studd, JWW. Immunoglobulins in normal pregnancy, pre-eclampsia and pregnancy complicated by nephrotic syndrome. J Obstet Gynaecol Br Commonwlth 1971; 78: 786–90.
97Dodson, MG, Kerman, RH, Lange, CF, Stefani, SS, O’Leary, JA. T and B cells in pregnancy. Obstet Gynecol 1977; 49: 299–302.
98Gleicher, N. Autoantibodies in normal and abnormal pregnancy. Am J Reprod Immunol 1992; 28: 269–73.
99Massobrio, M, Benedetto, C, Bertini, E, Tetta, C, Camussi, G. Immune complexes in preeclampsia and normal pregnancy. Am J Obstet Gynecol 1985; 152: 578–83.
100Jain, A, Rohatgi, P, Singh, VK, Sharma, MK. Circulating immune complexes in preeclampsia. J Indian Med Assoc 1991; 89: 251–53.
101Faulk, WP, Hunt, JS. Human trophoblast antigens. In: Rubin, JM, Gleicher, N eds, Immunology and allergy clinics of North America, reproductive immunology. Philadelphia: WB Saunders Co, 1990: 27–48.
102Hsi, B-L, Hunt, JS, Atkinson, JP. Differential expression of complement regulatory proteins on subpopulations of human trophoblast cells. J Repr Immunol 1991; 19: 209–23.
103Holmes, CH, Simpson, KL, Okada, H, Okada, N, Wainwright, SD, Purcell, DF et al. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol 1992; 22: 1579–85.
104Kovar, IZ, Riches, PG. C3 and C4 complement components and acute phase proteins in late pregnancy and parturition. J Clin Pathol 1988; 41: 650–52.
105Johnson, U, Gustavii, B. Complement components in normal pregnancy. Acta Pathol Microbiol Immunol Scand (C) 1987; 95: 97–99.
106Haeger, M, Unander, M, Bengtsson, A. Complement activation in relation to development of preeclampsia. Obstet Gynecol 1991; 78: 46–49.
107Chesley, LC. A short history of eclampsia. Obstet Gynecol 1974; 43: 599–602.
108Mauriceau, F. Traite des maladies des femmes grosses, et celles qui sont accouchées. Paris: d’Houry, 1964.
109Lindheimer, MD, Katz, AI. Hypertension in pregnancy. N Engl J Med 1985; 313: 675–80.
110Montan, S, Sjöberg, N-O, Svenningsen, N. Hypertension in pregnancy - fetal and infant outcome. A cohort study. Clin Exp Hypertens 1987; B6: 337–48.
111MacGillivray, I. Pre-eclampsia: the hypertensive disease of pregnancy. Philadelphia: WB Saunders, 1983.
112De Wolf, F, Robertson, WB, Brosens, I. The ultrastructure of acute atherosis in hypertensive pregnancy. Am J Obstet Gynecol 1975; 123: 164–74.
113Ferris, TF. Toxemia and hypertension. In: Burrow, GN, Ferris, TF eds, Medical complications during pregnancy. 3rd ed. Philadelphia: WB Saunders, 1988: 1–33.
114Pritchard, JA. Hypertensive disorders in pregnancy. In: Pritchard, JA, MacDonald, PC, Gant, NF eds, Williams obstetrics. 17th ed. Connecticut: Appleton-Century-Crofts, 1985: 525–60.
115Kitzmiller, JL, Benirschke, K. Immunofluorescent study of placental bed vessels in pre-eclampsia of pregnancy. Am J Obstet Gynecol 1973; 115: 248–51.
116Petrucco, OM, Thomson, NM, Lawrence, JR, Weldon, MW. Immunofluorescent studies in renal biopsies in pre-eclampsia. Br Med J 1974; 1: 473–76.
117Tedesco, F, Radillo, O, Candussi, G, Nazzaro, A, Mollnes, TE, Pecorari, D. Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae. Clin Exp Immunol 1990; 80: 236–40.
118Faulk, WP, Temple, A, Lovins, RE, Smith, N. Antigens of human trophoblast: a working hypothesis for their role in normal and abnormal pregnancies. Proc Natl Acad Sci USA 1978; 75: 1947–51.
119Campbell, DM, MacGillivray, I, Carr-Hill, R. Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol 1985; 92: 131–40.
120Feeney, JG, Scott, JS. Pre-eclampsia and changed paternity. Eur J Obstet Gynecol Repr Biol 1980; 11: 35–38.
121Ikedife, D. Eclampsia in multiparae. Br Med J 1980; 280: 985–86.
122Herrman, U, Marti, JJ. Immunogestosis: a new etiologic concept of essential EPH gestosis, with special consideration of the primigravid patient; preliminary report of a clinical study. Am J Obstet Gynecol 1977; 128: 489–93.
123Klonoff-Cohen, HS, Savitz, DA, Cefalo, RC, McCann, MF. An epidemiologic study of contraception and preeclampsia. JAMA 1989; 262: 3143–47.
124Need, JA, Bell, B, Meffin, E, Jones, WR. Pre-eclampsia in pregnancies from donor inseminations. J Reprod Immunol 1983; 5: 329–38.
125Serhal, PF, Craft, I. Immune basis for preeclampsia: evidence from oocyte recipients. Lancet 1987; 1: 744.
126Strickland, DM, Guzicks, DS, Cox, K, Gant, NF, Rosenfeld, CR. The relationship between abortion in the first pregnancy and development of pregnancy-induced hypertension in the subsequent pregnancy. Am J Obstet Gynecol 1986; 154: 146–48.
127Seidman, DS, Ever-Hadani, P, Stevenson, DK, Gale, R. The effect of abortion on the incidence of preeclampsia. Eur J Obstet Gynecol Repr Biol 1989; 33: 109–14.
128Toivanen, P, Hirvonen, T. Sex ratio of newborns: preponderance of males in toxemia of pregnancy. Science 1970; 170: 187–88.
129James, WH. The human sex ratio. Part 1: a review of the literature. Hum Biol 1987; 59: 721–52.
130Feeney, JG, Tovey, LAD, Scott, JS. Influence of previous blood-transfusion on incidence of pre-eclampsia. Lancet 1977; 1: 874–75.
131Arngrimsson, R, Bjornsson, S, Geirsson, RT, Bjornsson, H, Walker, JJ, Snaedal, G. Genetic and familial predisposition to eclampsia and pre-eclampsia in a defined population. Br J Obstet Gynaecol 1990; 97: 762–69.
132Robertson, WB, Brosens, I, Dixon, HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol 1967; 93: 581–92.
133Cignetti, M, Garzetti, GG, Marchegiani, F, Fabris, N, Romanini, C. Natural killer cells and Tac antigen in the hypertension of pregnancy. Clin Exp Obstet Gynecol 1990; 17: 13–15.
134Bardeguez, AD, McNerney, R, Frieri, M, Verma, UL, Tejani, N. Cellular immunity in preeclampsia: alterations in T-lymphocyte subpopulations during early pregnancy. Obstet Gynecol 1991; 77: 859–62.
135Schroksnadel, H, Fuchs, D, Herold, D, Wachter, H, Dapunt, O. Activated macrophages in preeclampsia. Pteridines 1993; 4: 144–48.
136Pacher, R, Redl, H, Frass, M, Petzl, DH, Schuster, E, Woloszczuk, W. Relationship between neopterin and granulocyte elastase plasma levels and the severity of multiple organ failure. Crit Care Med 1989; 17: 221–26.
137Strohmaier, W, Redl, H, Schlag, G, Inthorn, D. D-erythro-neopterin plasma levels in intensive care patients with and without septic complications. Crit Care Med 1987; 15: 757–60.
138Haeger, M, Unander, M, Bengtsson, A. Neopterin PMN elastase, and complement components as monitoring parameters in women with the syndrome of hemolysis, elevated liver enzymes and low platelet count. Pteridines 1993; 4: 138–43.
139Goris, RJA. Multiple organ failure: whole body inflammation? Schweiz med Wochenschr 1989; 119: 347–53.
140Jenkins, DM, Need, JA, Scott, JS, Morris, H, Pepper, M. Human leukocyte antigens and mixed lymphocyte reaction in severe preeclampsia. Br Med J 1978; 1: 542–44.
141Johnson, N, Moodley, J, Hammond, MG. Human leukocyte antigen status in African women with eclampsia. Br J Obstet Gynaecol 1988; 95: 877–79.
142Redman, CWG, Bodmer, WF, Bodmer, JG, Beilin, LJ, Bonnar, J. HLA antigens in severe preeclampsia. Lancet 1978; 2: 397–99.
143Kilpatrick, DC, Liston, WA, Gibson, F, Livingstone, J. Association between susceptibility to preeclampsia within families and HLA-DR4. Lancet 1989; 2: 1063–65.
144Hoff, C, Stevens, RG, Mendenhall, H, Peterson, RDA, Spinnato, JA. Association between risk for preeclampsia and HLA-DR4. Lancet 1990; 1: 660–61.
145Wilton, AN, Cooper, DW, Brennecke, SP, Bishop, SM, Marshall, P. Absence of close linkage between maternal genes for susceptibility to preeclampsia/eclampsia and HLA-DR beta. Lancet 1990; 336: 653–57.
146Houwert-de Jong, MH, Claas, FHJ, Gmelig-Meyling, FHJ, Kalsbeek, GL, Valentijn, RM, the Velde, ER et al. Humoral immunity in normal and complicated pregnancy. Eur J Obstet Gynecol Reprod Biol 1985; 19: 205–14.
147Kaku, M. Placental polysaccharide and the aetiology of the toxaemia of pregnancy. J Obstet Gynaecol Br Emp 1957; 60: 148–56.
148Hulka, JF, Brinton, V. Antibody to trophoblast during early postpartum period in toxemic pregnancy. Am J Obstet Gynecol 1963; 86: 130–34.
149Gaugas, JM, Curzen, P. Complement fixing antibody against solubilized placental microsomal fraction in pre-eclampsia sera. Br J Pathol 1974; 55: 570–73.
150Thiry, L, Yane, F, Sprecher-Goldberger, S, Cappel, R, Bossens, M, Neuray, F. Expression of retrovirus related antigen in pregnancy. II. Cytotoxic and blocking specificities in immunoglobulins eluted from the placenta. J Reprod Immunol 1981; 2: 323–30.
151Bieglmayer, C, Rudelstorfer, R, Bartl, W, Janisch, H. Detection of antibodies in pregnancy serum reacting with isolated placental basement membrane collagen. Br J Obstet Gynaecol 1986; 93: 815–22.
152Branch, DW, Andres, R, Digre, KB, Rote, NS, Scott, JR. The association of antiphospholipid antibodies with severe preeclampsia. Obstet Gynecol 1989; 73 541–45.
153Alanen, A. Serum IgE and smooth muscle antibodies in preeclampsia. Ada Obstet Gynecol Scand 1984; 63: 581–82.
154Foidart, JM, Hunt, J, Lapiere, C-M, Nusgens, B, De Rycker, C, Bruwier, M et al. Antibodies to laminin in preeclampsia. Kidney Int 1986; 29: 1050–57.
155Samuels, P, Main, EK, Tomaski, A, Mennuti, MT, Gabbe, SG, Cines, DB. Abnormalities in platelet antiglobulin tests in preeclamptic mothers and their neonates. Am J Obstet Gynecol 1987; 157: 109–13.
156Rapaport, VJ, Hirata, G, Yap, HK, Jordan, SC. Anti-vascular endothelial cell antibodies in severe preeclampsia. Am J Obstet Gynecol 1990; 162: 138–46.
157Haeger, M, Unander, AM, Bengtsson, A. Enhanced anaphylatoxin and terminal C5b-9 complement formation in patients with the syndrome of hemolysis, elevated liver enzymes and low platelet count. Obstet Gynecol 1990; 76: 698–702.
158Loke, YW, Joysey, VG, Borland, R. HL-A antigens on human trophoblast cells. Nature 1971; 232: 403–405.
159Bengtsson, A, Heideman, M. Altered anaphylatoxin activity during induced hypoperfusion in acute and elective abdominal aortic surgery. J Trauma 1986; 26: 631–37.
160Bengtsson, A, Haljamae, H. Complement activation and organ function in critically ill surgical patients. Acute Care 1988–1989; 14–15: 111–37.
161Bengtsson, A, Holmberg, P, Heideman, M. The ischaemic leg as a source of complement activation. BrJSurg 1987; 74: 697–700.
162Chenoweth, DE, Hugli, TE. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 1978; 75: 3943–47.
163Walport, M. Complement. In: Roitt, I, Brostoff, J, Male, D eds, Immunology, 2nd ed. London: Churchill Livingstone, 1989: 13.1–13.16.
164Hangen, DH, Stevens, JG, Satoh, PS, Hall, EW, O'Hanley, PT, Raffin, TA. Complement levels in septic primates treated with anti-C5a antibodies. J Surg Res 1989; 46: 195–99.
165Greer, IA, Haddad, NG, Dawes, J, Johnston, TA, Johnstone, FD, Steel, JM. Increased neutrophil activation in diabetic pregnancy and in nonpregnant diabetic women. Obstet Gynecol 1989; 74: 878–81.
166Sunder-Plassmann, G, Stockenhuber, F, Balcke, P. Serum interleukin 2 activity in renal graft recipients. Transplant Proc 1988; 20: 387–89.
167Sunder-Plassmann, G, Derfler, K, Wagner, L, Stockenhuber, F, Endler, M, Nowotny, C et al. Increased serum activity of interleukin-2 in patients with pre-eclampsia. J Autoimmun 1989; 2: 203–205.
168Weisman, HF, Bartow, T, Leppo, MK, March, HC Jr, Carson, GR, Concino, MF et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis. Science 1990; 249: 146–51.
169Yeh, CG, Marsh, HC Jr, Carson, GR, Berman, L, Concino, MF, Scesney, SM et al. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive Arthus reaction in rats. J Immunol 1991; 146: 250–56.
170Gerard, NP, Gerard, C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991; 349: 614–17.
171Exley, AR, Cohen, J, Buurman, W, Owen, R, Hanson, G, Lumley, J et al. Monoclonal antibody to TNF in severe septic shock. Lancet 1990; 1: 1275–76.
172Manning, PJ, Watson, RM, Margolskee, DJ, Williams, VC, Schwartz, JI, O'Byrne, PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990; 323: 1736–39.
173Mandell, GL. ARDS, neutrophils, and pentoxifylline. Am Rev Respir Dis 1988; 138: 1103–105.